ArticleScientific reports2025
Bioinformatics and experimental insights into F2RL1 as a key biomarker in cervical cancer diagnosis and prognosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer(CCa) remains a significant global public health concern, with early diagnosis and treatment being crucial. Moreover, the molecular mechanisms underlying its pathogenesis remain incompletely elucidated. F2RL1 is closely associated with various tumors. However, its relationship with CCa is poorly understood. We accessed data from 309 patients diagnosed with CCa from TCGA database. The Limma package facilitated differential expression analysis to identify differentially expressed mRNAs (DEmRNAs). Survival analysis and ROC analysis were conducted via the XIANTAO database. Immune-related genes were identified with F2RL1-related genes through ImmPort database analysis. Functional enrichment analysis was carried out using GO, KEGG, and GSEA. We gathered cervical cells and serum from participants to test for HPV and TCT, and then used qPCR to check the levels of F2RL1 mRNA expression. We also verified the expression of F2RL1 protein through WB and ELISA techniques. Our investigation has unveiled a fascinating discovery-the levels of F2RL1 expression in CCa tissues are notably elevated when compared to normal tissues, showcasing intriguing variations among various pathological types. Moreover, the presence of high F2RL1 expression is linked to reduce Overall Survival (OS), Progression Free Interval (PFI), Progression Free Survival (PFS). F2RL1 rocked the ROC analysis with an AUC of 0.996. Furthermore, F2RL1 expression levels significantly impact CCa in different N stages, pathological tissue types, treatment statuses, and racial groups, allowing us to develop a predictive model. Additionally, we identified 43 immune-related genes. Enrichment analysis highlighting their association with pathways related to cell movement and T cell activation. Through analysis, we discovered an inverse proportion between F2RL1 expression and the infiltration of most immune cells, particularly TFH and cytotoxic cells, suggesting a potential link to immune evasion in CCa. Molecular biology experiments also confirmed a significant increase in F2RL1 expression in cervical exfoliated cells and serum. Our research uncovers the predictive and early detection significance of F2RL1 in CCa and its correlation with immune infiltration for the first time. F2RL1 is strongly linked to the progression of CCa and could serve as a biomarker for the early diagnosis and prognosis of CCa patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.